Last reviewed · How we verify

L-AmB standard dose — Competitive Intelligence Brief

L-AmB standard dose (L-AmB standard dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polyene antifungal. Area: Infectious Disease.

phase 3 Polyene antifungal Ergosterol (fungal cell membrane sterol) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

L-AmB standard dose (L-AmB standard dose) — Federal University of Health Science of Porto Alegre. L-AmB (liposomal amphotericin B) binds to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and lead to cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
L-AmB standard dose TARGET L-AmB standard dose Federal University of Health Science of Porto Alegre phase 3 Polyene antifungal Ergosterol (fungal cell membrane sterol)
Abelcet AMPHOTERICIN B Astellas Pharma marketed Lipid-based Polyene Antifungal [EPC] 1964-01-01
Mycostatin nystatin Generic (originally Squibb) marketed Polyene Antifungal [EPC] Ergosterol (fungal cell membrane) 1954-01-01
Amphotericin B Deoxycholate Amphotericin B Deoxycholate Drugs for Neglected Diseases marketed Polyene antifungal Ergosterol
Amphotericin B Liposome Amphotericin B Liposome Aurobindo Pharma Ltd marketed Lipid-based Polyene Antifungal [EPC]
Liposomal Amphotericin B Liposomal Amphotericin B Taiwan Liposome Company marketed Polyene antifungal Ergosterol
Amphotericin B Lipid emulsion Amphotericin B Lipid emulsion Bharat Serums and Vaccines Limited phase 3 Polyene antifungal Ergosterol

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polyene antifungal class)

  1. Bharat Serums and Vaccines Limited · 1 drug in this class
  2. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
  3. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 drug in this class
  4. Dr. Falk Pharma GmbH · 1 drug in this class
  5. Drugs for Neglected Diseases · 1 drug in this class
  6. Federal University of Health Science of Porto Alegre · 1 drug in this class
  7. Fundacion Nacional de Dermatologia · 1 drug in this class
  8. Pfizer · 1 drug in this class
  9. Poitiers University Hospital · 1 drug in this class
  10. Taiwan Liposome Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). L-AmB standard dose — Competitive Intelligence Brief. https://druglandscape.com/ci/l-amb-standard-dose. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing